FGEN - FIBROGEN INC
IEX Last Trade
0.4898
0.066 13.373%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:50 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$0.42
0.07
15.44%
Fundamental analysis
36%
Profitability
43%
Dept financing
26%
Liquidity
37%
Performance
31%
Performance
5 Days
24.65%
1 Month
27.85%
3 Months
33.67%
6 Months
-57.38%
1 Year
-34.58%
2 Year
-96.81%
Key data
Stock price
$0.49
DAY RANGE
$0.42 - $0.51
52 WEEK RANGE
$0.31 - $2.93
52 WEEK CHANGE
-$38.38
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Enrique A. Conterno
Region: US
Website: fibrogen.com
Employees: 570
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: fibrogen.com
Employees: 570
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
FibroGen, Inc. discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan. Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor, is in Phase III.
Recent news